Trials / Not Yet Recruiting
Not Yet RecruitingNCT04052191
MCRcI® Stem Cell Treatment for Diffuse Coronary Artery Disease
Intra-Coronary Administration of MCRcI® (Myo-Cardial Regenerative Cellular Injection) Improves Left Ventricular Function in Patients With Diffuse Coronary Artery Disease
- Status
- Not Yet Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- Sponsor
- Honya Medical Inc · Industry
- Sex
- All
- Age
- 20 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
Safety evaluation of Intra-Coronary Administration of MCRcI® stem cells in Patients with Diffuse Coronary Artery Disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | MCRcI® stem cells | Intra-Coronary Administration of MCRcI® stem cells |
Timeline
- Start date
- 2025-12-01
- Primary completion
- 2026-01-01
- Completion
- 2026-12-01
- First posted
- 2019-08-09
- Last updated
- 2024-10-03
Locations
1 site across 1 country: Taiwan
Source: ClinicalTrials.gov record NCT04052191. Inclusion in this directory is not an endorsement.